Fagron stock
Price history
+19.61% over the period1 year: from €20.40 (November 17, 2025) to €24.40 (November 17, 2026), +19.61%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | €24.40 |
| October 30, 2026 | €23.45 |
| September 30, 2026 | €23.25 |
| August 31, 2026 | €22.25 |
| July 31, 2026 | €23.20 |
| June 30, 2026 | €24.10 |
| May 29, 2026 | €24.10 |
| April 30, 2026 | €24.00 |
| March 31, 2026 | €21.60 |
| February 27, 2026 | €22.75 |
| January 30, 2026 | €22.15 |
| December 31, 2025 | €21.30 |
| November 28, 2025 | €21.30 |
| November 17, 2025 | €20.40 |
At a glance
The company
Pharmaceutical compounding company delivering personalized care products and services to hospitals, pharmacies, clinics and patients worldwide
Latest results
Quarter to September 30, 2026
Next event
TickerLandia's take on Fagron
- Priced as usual relative to earnings: P/E on the latest fiscal year 20 vs a median of 18 over its last 9 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 19 vs 19 (−1%) in a group of 10.
- Strong point: Earnings stability (79/100 in its group). Weak point: Financial strength (30/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.56% from the 52-week high
Analysts · 6 analysts
Average target€29.00+18.85% vs. price
Buy 6 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: Fagron
Compared with similar companies: high earnings stability, low risk, and low price.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow29
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 18.8 30 Forward P/E 15.9 30 EV/EBITDA 12.1 33 Price/book 2.77 43 Price/sales 1.60 9 Profitabilitylow38
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 14.3% 28 Gross margin 44.4% 14 Net margin 8.9% 22 ROE 16.7% 70 ROA 7.0% 54 Earnings stabilityhigh79
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.8% 96 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh61
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +11.66% 70 Revenue growth (year over year) +16.04% 58 Earnings growth (year over year) +1.61% 54 Financial strengthlow30
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.70 36 Interest coverage 7.32 29 Debt/equitycounts in reverse: lower means more financial strength 1.06 10 Current ratio 1.77 43 Dividendaverage42
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 9 years 33 Dividend yield 1.7% 55 Payout ratio 32.0% 38 Market momentumstrong61
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +19.61% 62 Distance from 200-day average +5.66% 61 Risklow28
How much the price swings.
Metric Value Position in group Volatility (60 days) 23.5% 35 Maximum drawdown (12 months) 16.8% 21
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Fagron is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Fagron's P/E today is 19.7, in line with the median of its last 9 fiscal years (17.6; between 13.9 and 25.8 from 2017 to 2025). Fagron's P/E (trailing 12 months): 18.8, in line with the median of a group of 10 similar companies (19.0).
Compared with 10 similar companies
| Metric | Fagron | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 18.8 | Middle | |
| Forward P/E | 15.9 | Middle | |
| Operating margin | 14.3% | Middle | |
| ROE | 16.7% | Middle | |
| Debt/equity | 1.06 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Fagron. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€552.48M
Latest quarter · Q2 2026
Net income
€46.28M
Latest quarter · Q2 2026
Quarterly net margin
8.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €1.73B
- P/E
- 18.8
- EPS
- €1.25
- Volume
- 138.87K
- Daily trading
- €2.42M
- Dividend yield
- 1.64%
- Last ex-dividend on May 18, 2026
How Fagron is changing
All resultsRevenue grew 11.4% a year on average over the last 5 years
Operating margin rose from 13.4% to 15.2%
Profits turn into cash: free cash flow equal to 135% of net income
Returns
Fagron returns with dividends
€1,000 invested in Fagron 5 years ago, on November 17, 2021, would be worth €1,830 today with dividends reinvested: +83.00% in total, +12.85% per year. On price alone it would be €1,697 (+69.68%).
| Period | Fagron | €1,000 becomes |
|---|---|---|
| 1 month | +4.95% | €1,049 |
| 6 months | +0.21% | €1,002 |
| Year to date | +14.55% | €1,146 |
| 1 year | +21.60% | €1,216 |
| 3 years | +46.92% | €1,469 |
| 5 years | +83.00% | €1,830 |
| 10 years | +214.41% | €3,144 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Fagron: technical analysis
Fagron shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 41.2% below its all-time closing high (€41.48, August 5, 2014).
- Trend
- No clear trend
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- +5.66%
Support and resistance
Price areas where Fagron has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€25.05+2.66%2 touches, last on June 10, 2026
- Resistance€24.80+1.64%3 touches, last on November 10, 2026
- Last price€24.40
- Support€23.98−1.71%3 touches, last on July 30, 2026
- Support€23.60−3.28%4 touches, last on September 28, 2026
- Support€23.30−4.51%3 touches, last on November 2, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 23.5%
- Largest fall in the last year
- −16.83%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Fagron: seasonality
Average monthly price change over 19 years
Over the last 19 years, the strongest month for Fagron has been April: +6.27% on average, positive in 16 years out of 19. The weakest has been November: −3.52% on average, positive in 8 years out of 19.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.58% | +2.26% | 12 of 19 |
| February | +3.89% | +2.39% | 12 of 19 |
| March | +2.47% | +2.41% | 11 of 19 |
| April | +6.27% | +7.18% | 16 of 19 |
| May | +2.48% | +0.42% | 10 of 19 |
| June | −2.69% | −3.19% | 8 of 19 |
| July | −0.07% | −2.97% | 7 of 19 |
| August | −0.62% | +1.37% | 13 of 19 |
| September | −0.74% | −2.07% | 6 of 19 |
| October | −0.55% | +0.21% | 11 of 19 |
| November | −3.52% | −0.63% | 8 of 19 |
| December | +1.94% | +3.96% | 12 of 19 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Fagron and its competitors
Pharmacies and hospitals know Fagron NV through brands such as DiluCap excipients, DiluTab, Pigmerise, Nourisil MD and SyrSpend SF, along with the Neogen and TrichoConcept hair care lines. The company, formerly known as Arseus NV until it changed its name in January 2015, provides personalized pharmaceutical care to hospitals, pharmacies, clinics and patients in markets worldwide. Its activity is organized in three segments: Essentials, Brands and Compounding Services. It also trains prescribers, hospitals and pharmacists through the Fagron Academy.
- Headquarters
- Nazareth, Belgium
- Employees
- 4,880
- Founded
- 1990
- Chief executive
- Rafael Padilla
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| FagronFAGR | $1.9B | 14.3% | 18.8 | +0.21% |
| Faes FarmaFAE | $1.73B | 13.0% | 18.7 | +9.03% |
| AlmirallALM | $2.53B | 9.6% | 32.1 | −7.24% |
| Siegfried HoldingSFZN | $3.53B | 16.7% | 17.3 | −14.20% |
| Laboratorios Farmaceuticos RoviROVI | $3.93B | 20.2% | 17.4 | +16.20% |
| PharmaNutraPHN | $875.44M | 21.7% | 35.0 | −3.45% |
Same industry or related industries, similar size. Compare Fagron with its competitors · Full profile
